MAP Pharmaceuticals (MAPP) Stock Price, News & Analysis

Company Overview

MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.

Key Stats

• Today's Range: $23.44 to $23.44
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 2.40%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Ex-Dividend for 12/26 Dividend: 12/20/2024
• Dividend Payable: 12/26/2024
• Today: 1/29/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MAPP
• CUSIP: N/A
• CIK: 1401923
• Web: N/A
• Phone: +1-302-6587581
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A